Quarterly Financial Results and Upcoming Conference - Research Reports on Mylan, Aegerion, Bard, Incyte and Boston Scientific

NEW YORK, November 5, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Mylan Inc. (NASDAQ: MYL), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), C.R. Bard, Inc. (NYSE: BCR), Incyte Corporation (NASDAQ: INCY) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7704-100free.

--
Mylan Inc. Research Reports
On October 30, 2014, Mylan Inc. (Mylan) reported its Q3 2014 financial results with net earnings attributable to Mylan common shareholders more than tripled to $499.1 million, from net earnings of $158.9 million in Q3 2013. The Company reported Q3 2014 total revenues of $2.08 billion, up 17.9% YoY, reflecting growth across both segments: Generics Third Party net sales and Specialty Third Party net sales, while also surpassing Thomson Reuters analyst estimate of $2.06 for the quarter. The Company's Q3 2014 adjusted diluted EPS stood at $1.16, surpassing EPS of $1.14 predicted by 10 analysts polled by Thomson Reuters. The Company reported 9M 2014 total revenues of $5.6 billion, up 10.5% YoY, and net earnings attributable to Mylan common shareholders of $740.2 million, up 66.9% YoY. The Company expects its Q4 2014 adjusted diluted EPS between $1.03 and $1.09, while for full-year 2014, total revenue is expected between $7.7 billion and $7.8 billion and adjusted diluted EPS in the range of $3.54 and $3.60. The full research reports on Mylan are available to download free of charge at:

http://www.analystsreview.com/Nov-05-2014/MYL/report.pdf

--
Aegerion Pharmaceuticals, Inc. Research Reports
On October 30, 2014, Aegerion Pharmaceuticals, Inc. (Aegerion) reported a staggering 167.4% YoY improvement in its Q3 2014 net product sales to $43.7 million. The Company stated that 91% of net product sales in Q3 2014 were from the U.S., representing growth of 18% YoY. The Company also trimmed its Q3 2014 net loss to $5.9 million, from net loss of $12.5 million in Q3 2013. The Company reported 9M 2014 net product sales of $106.7 million, up 343.5% YoY, while net loss stood at $31.3 million, compared to net loss of $49.5 million in 9M 2013. For full-year 2014, the Company expects JUXTAPID net product sales between $150 million and $160 million, while for full-year 2015, the Company expects to achieve revenue growth in the range of 30-40% over full-year 2014 projected revenue. The full research reports on Aegerion are available to download free of charge at:

http://www.analystsreview.com/Nov-05-2014/AEGR/report.pdf

--
C.R. Bard, Inc. Research Reports
On October 22, 2014, C.R. Bard, Inc. (Bard) reported Q3 2014 net sales of $830.0 million, up 9.5% YoY, reflecting growth across all product groups and surpassing Thomson Reuters consensus revenue estimate of $818.88 million for the quarter. The Company's Q3 2014 net income stood at $131.3 million or $1.69 per diluted share, compared to net income of $93.2 million or $1.15 per diluted share in Q3 2013. The Company's Q3 2014 adjusted EPS stood at $2.15, surpassing average EPS (excluding special items) estimate of $2.14 for the quarter which was generated through 17 analysts polled by Thomson Reuters. The Company's 9M 2014 net sales improved 8.8% YoY to $2.5 billion, while net income improved by a staggering 618.8% YoY to $160.3 million. The full research reports on Bard are available to download free of charge at:

http://www.analystsreview.com/Nov-05-2014/BCR/report.pdf

--
Incyte Corporation Research Reports
On October 30, 2014, Incyte Corporation's (Incyte) stock surged 10.90% to close the trading session at $64.18, as the Company reported its Q3 2014 and 9M 2014 financial results. The Company posted Q3 2014 net income of $59.3 million or $0.33 per diluted share, compared to net loss of $22.0 million or $0.14 diluted loss per share in Q3 2013. The Company's Q3 2014 total revenues improved by an astounding $132.8% YoY to $198.1 million, led by 62.5% YoY growth in net product revenues to $97.8 million and 421.7% YoY growth in contract revenues to $88.2 million. According to Zacks, the Company was expected to report Q3 2014 EPS of $0.02 on revenue of $161.2 million. The Company's 9M 2014 total revenues improved 50.3% YoY to $387.5 million, while net loss stood at $11.5 million, compared to net loss of $40.3 million in 9M 2013. For full-year 2014, the Company expects Jakafi net product revenues in the range of $350 million - $360 million, driven by continued strong growth in underlying demand. The full research reports on Incyte are available to download free of charge at:

http://www.analystsreview.com/Nov-05-2014/INCY/report.pdf

--
Boston Scientific Corporation Research Reports
On October 30, 2014, Boston Scientific Corporation (Boston Scientific) announced that the Company will participate in the upcoming 2014 Credit Suisse Annual Healthcare Conference on November 11, 2014, in Phoenix, Arizona. In addition, the Company's Vice President and CFO, Dan Brennan, will give a presentation about the Company beginning at approximately 8:00 a.m. PT followed by a question and answer session. A live webcast of the presentation and question and answer session will be available on the Company's official website. The full research reports on Boston Scientific are available to download free of charge at:

http://www.analystsreview.com/Nov-05-2014/BSX/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review